UNSPSC 51181630: Thiamazole

This classification denotes an antithyroid agent with the molecular formula C4H6N2S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 554Z48XN5E, chemically known as 1,3-dihydro-1-methyl-2h-imidazole-2-thione but more generally known as methimazole, which bears U.S. National Institutes of Health Compound Identifier 1349907. European Medicines Agency schedules Thiamazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10967MIG.

The term THIAMAZOLE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules methimazole in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.

UNSPSC 51181630 Thiamazole is a Commodity code covering thyroid-suppressing pharmaceutical agents supplied through state and local cooperative purchasing vehicles. State and local governments buy thiamazole primarily through multistate cooperative purchasing alliances that aggregate demand across participating state agencies, counties, and other public health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serves as the dominant issuing body for this commodity, establishing master agreements with pharmaceutical manufacturers to supply generic and brand-name drugs including thiamazole to participating jurisdictions across multiple states. These procurements emphasize compliance with cGMP and Drug Supply Chain Security Act requirements, management of supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), and detailed product tracking by National Drug Code, SKU, UPC, and strength specifications.

MMCAP's RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products, posted January 20, 2026 with responses due March 26, 2026, represents current activity under the code. The solicitation seeks multiple awards from manufacturers willing to supply thiamazole and related thyroid agents at competitively priced rates, with contract term beginning July 1, 2026 and running two years (with optional renewals for incumbent vendors through June 30, 2028). Award decisions weight price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing format (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent). Vendors must maintain commercial general liability coverage of $5 million per occurrence, supply through authorized wholesalers with chargeback systems, and deliver products with minimum six-month shelf life at manufacture. The cooperative purchasing structure extends across Minnesota, Oregon, and other member jurisdictions, enabling individual state and local agencies to access awarded pricing without conducting separate RFPs.